P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.

@inproceedings{Finn2011P11705PR,
  title={P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.},
  author={Richard S. Finn and J. K. Crown and Katalin Bo{\'e}r and Istv{\'a}n L{\'a}ng and Rupesh J. Parikh and Ravindranath Patel and Marcus Schmidt and Christopher T. Hagenstad and Hyun Jung Lim and Tam{\'a}s Pint{\'e}r and Dino Amadori and David Yin Kai Chan and R. Dichmann and Janice M. Walshe and Aurora Breazna and Sindy T. Kim and Sophia S Randolph and Dennis J Slamon},
  year={2011}
}
Background: PD 0332991 is an orally bioavailable selective inhibitor of CDK 4/6 and prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Preclinical evaluations suggest that reduction in CDKN2A (p16) expression and cyclin D1 (CCND1) overexpression confer susceptibility to PD 0332991 (Finn 2009). In addition, PD 0332991 was synergistic in combination with tamoxifen in vitro in ER+ human breast cancer cell lines. Based on these observations, a… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.

  • International journal of cancer and clinical research
  • 2015
VIEW 16 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Vakaramoko Diaby, Georges Adunlin, +4 authors Alberto J. Montero
  • Breast Cancer Research and Treatment
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

Molecular pathways: CDK4 inhibitors for cancer therapy.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND